ConjuChem

ConjuChem is a biotechnology company that aims to revolutionize the future of biotechnology with groundbreaking therapeutic innovations. Founded in 1997 as ConjuChem Biotechnologies Inc. of Montreal, Quebec, Canada, the company is now based in Los Angeles, CA. Their focus lies in discovering novel therapeutics, with an initial emphasis on diabetes. Their proprietary technology platforms, Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™), enable the creation of new drugs with enhanced therapeutic activity, longer duration of action, improved tolerability, and increased efficacy. This addresses the common challenge of short durations of in vivo activity that limit commercial viability. With several in-house research programs and one product undergoing clinical development, ConjuChem is dedicated to discovering and developing new drugs. Their technology platforms hold broad applicability for multiple indications, making the company open to partnership agreements and collaborations within the biopharmaceutical industry. The company recently secured a $12.00M Private Equity Round investment from BMO Nesbitt Burns on 27 June 2003. This investment reflects confidence from the investor and signifies potential growth for ConjuChem.